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Helicobacter pylori (H. pylori) is one of the
most common human pathogens that affected about
50% of the human population (1). H. pylori is a
Gram-negative, microaerophilic, spiral bacterium
that permanently or temporarily inhabits various
parts of the gastric mucosa. H. pylori is the main
pathogenic factor of gastroduodenal diseases: gastri-
tis B, gastric ulcer, duodenal ulcer, gastric cancer,
gastric lymphoma MALT (Mucosa Associated
Lymphoid Tissue) and MÈnÈtrierís disease.
Moreover, various studies reveal a relation of H.
pylori to the development of coronary heart disease,
stomatitis, liver diseases (hepatic encephalopathy,
neoplasms), skin diseases and allergy (2ñ12).
Eradication of H. pylori is recommended at
every stage of the disease (3). Introduction of the
effective therapy guarantees eradication of the infec-
tion, which results in the relief and often in the
regression of disorder changes that otherwise might
lead to gastric cancer, which develops in 2% of indi-
viduals infected with H. pylori (5, 13, 14).
Indications for the treatment and guidelines for
clinical trials are elaborated by the European
Helicobacter Study Group (EHSG) (1, 15). On the
basis of these recommendations, the Working Group
of the Polish Society of Gastroenterology (PTG ñ pl.
Polskie Towarzystwo Gastroenterologiczne) has
issued guidelines that are obligatory in Poland.
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Abstract: An increasing resistance of Helicobacter pylori (H. pylori) to antimicrobial agents leads to the need
of regional monitoring of the prevalence resistant strains (according to the Maastricht/Florence consensus
report, 2012). The aim of the study was to assess the resistance to levofloxacin of H. pylori strains isolated from
adult patients of Ma≥opolska region in Poland. Bioptates taken from gastric mucosa during gastroscopy consti-
tuted the material for the study. Two hundred ten H. pylori strains were isolated from 811 patients. A majority
of strains (171) came from patients before the treatment of H. pylori infections while the remaining 39 strains
were isolated from patients after the failed therapy. Susceptibility of H. pylori to levofloxacin was determined
by strips impregnated with antibiotic gradient (E-test, bioMerieux). The obtained minimum inhibitory concen-
tration (MIC) values ranged from 0.002 mg/L to 32 mg/L. The percentage of strains resistant to levofloxacin
amounted to 8.10% (17/210). Among the group of strains isolated from patients before the treatment, 5.85%
(10/171) of H. pylori strains were resistant to levofloxacin. In the group of strains isolated from patients after
the treatment 17.95% (7/39) of strains were resistant. The difference in the frequency of H. pylori strains resist-
ant to levofloxacin in patients before and after the treatment of the infection due to H. pylori was statistically
significant (p = 0.0297). The low percentage of H. pylori strains resistant to levofloxacin justify that the intro-
duction of a triple therapy with levofloxacin is a good alternative in the treatment of H. pylori infections, espe-
cially in regions with high prevalence of H. pylori strains resistant to clarithromycin (> 20%). 
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Current obligatory recommendations in Poland were
established by PTG in 2008 (5) on the basis of
Maastricht Consensus 2005 by EHSG. Now, there
are no new recommendations based on the newest
Maastricht/Florence Consensus 2012. According to
all these recommendations, the treatment of H.
pylori infection is a combined empirical therapy
including three types of drugs: gastric antisecretory
drugs, cytoprotective drugs and antimicrobial
agents. 
Current regimens of the treatment of H. pylori
infections in Poland (2008) are shown in Table 1
and new recommendations in Europe (2012) are
shown in Table 2. The difference between these rec-
ommendations are as follows:
ñ variability of the treatment of H. pylori infec-
tions in regions with low (<20%) and high
(>20%) prevalence of H. pylori strains resistant
to clarithromycin; Maastricht/Florence IV con-
sensus report recommended to abandon clar-
ithromycin in treatment H. pylori infections or
perform previous susceptibility testing to cla-
rithromycin in regions with high prevalence of
H. pylori strains resistant to clarithromycin. 
ñ 2nd line treatment schemes contain levo-
floxacin, whereas in the older version levo-
floxacin was only a proposal in the 3rd line
treatment;
ñ in Maastricht/Florence IV consensus report it
is strongly recommended that the 3rd line treat-
ment have to be based on the susceptibility
testing. 
According to the new Maastricht/Florence
Consensus 2012, the scheme for the region with the
high prevalence of H. pylori strains resistant to cla-
rithromycin should be introduced in Poland. Recent
studies showed that 34% of strains were resistant to
clarithromycin in Southern Poland (16). According
to PTG data from 2008, the resistance of H. pylori to
antibacterial drugs used in the therapy is high in
Poland and amounts to 28% to clarithromycin (pri-
mary resistance 22%, secondary resistance 54%)
and 46% to metronidazole (primary resistance 41%,
secondary resistance 68%) (5). H. pylori strains
Table 2. Schemes of the treatment of H. pylori infections according to the new guidelines ñ Maastricht/Florence Consensus 2012. 
Prevalence of H. pylori strains resistant to clarithromycin
Low (< 20%) High (> 20%)
1st line treatment PPI + CH + AC/MZ or Quadruple bismuth therapy or ñ if not available
Quadruple bismuth therapy sequential or concomitant non-bismuth therapy
2nd line treatment Quadruple bismuth therapy or PPI + LE + AC
PPI + LE + AC
3rd line treatment Based on susceptibility testing only
PPI ñ proton pomp inhibitor; CH ñ clarithromycin; AC ñ amoxicillin; MZ ñ metronidazole, LE ñ levofloxacin
Table 1. Treatment of H. pylori infections (5)
The first-line treatment (one of the following):
PPI, AC (1000 mg), MZ (500 mg) ñ twice a day, 10ñ14 days.
PPI, CH (500 mg), MZ (500 mg) ñ twice a day, 10ñ14 days.
PPI, AC (500 mg), CH(500 mg) ñ twice a day, 10ñ14 days.
The second-line treatment (one of the following):
PPI, AC(1000 mg), MZ (500 mg) ñ twice a day, and TC (250 mg) ñ three times daily; prolonged to 14 days.
PPI, AC (1000 mg), MZ (500 mg) ñ twice a day, and bismuth salts (120 mg) ñ four times daily; prolonged to 14 
days.
The third-line treatment: 
Evaluation of the susceptibility of the strains to the currently used antimicrobial agents.
Possible introduction of levofloxacin.
Adding a probiotic. 
PPI ñ proton pomp inhibitor; CH ñ clarithromycin; AC ñ amoxicillin; MZ ñ metronidazole, TC ñ tetracycline
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resistant to amoxicillin have not been found in
Poland (5, 17). As a result of the frequent adminis-
tration of clarithromycin and metronidazole in the
treatment of infections due to H. pylori, bacterial
strains simultaneously resistant to both drugs can be
found (17ñ19). An increasing resistance of H. pylori
bacteria as well as their multi-drug resistance to rou-
tinely used antimicrobial agents is a serious thera-
peutic problem.
Current recommendation of PTG is to consider
the introduction of the scheme: levofloxacin +
amoxicillin with PPI as a 3rd line empirical treat-
ment, whereas EHSG recommended this scheme as
a 2nd line treatment. 
Levofloxacin (S-enantiomer of ofloxacin) is a
chemotherapeutic agent of the 3rd generation fluoro-
quinolones with a broad-spectrum activity. The
development of the resistance of H. pylori strains to
fluoroquinolones is a result of point mutations
occurring mainly at positions 87 and 91 of gyrA
gene that encodes gyrase, a binding site for
quinolones in Gram-negative bacteria (20). 
The introduction of levofloxacin to the treat-
ment schemes raises many hopes. Many studies
have shown the high efficiacy of treatment schemes
with levofloxacin (21ñ24). 
The lack of data on the susceptibility of H.
pylori strains isolated in Poland to levofloxacin con-
stituted a base for performing the research to assess
the level of the susceptibility to levofloxacin of H.
pylori strains isolated from dyspeptic patients
between the years 2006ñ2012.
MATERIALS AND METHODS
Patients and clinical material
In total, 811 dyspeptic patients (429 women,
382 men), with indications to gastroscopy, were
enrolled to the study between 2006ñ2012. Medium
age of patients was 45 years (16ñ87 years). Patients
underwent gastroscopy in selected Gastroenterology
Clinic in KrakÛw, Southern Poland. According to
the clinical diagnosis, there were two main groups of
patients: First group covered individuals with peptic
ulcer disease (PUD), means patients with gastric or
duodenal ulceration, and second group covered indi-
viduals with non-ulcer dyspepsia (NUD) means
patients with diseases of upper gastrointestinal tract
other than peptic ulcer disease, e.g., gastritis, duo-
denitis, esophagitis. 
Two bioptates were taken from each patient
during gastroscopy from the antrum and the body of
the stomach. In total, 210 H. pylori strains were iso-
lated from bioptates. These H. pylori strains were
obtained from 210 patients (115 women, 95 men),
including 51 patients with PUD and 159 patients
with NUD. Eighty one percent of these H. pylori
strains (171/210) were isolated from patients before
the treatment of H. pylori infections, while 19%
(39/210) strains were derived from patients after the
failed therapy. 
The plan of the study was approved by the
Bioethical Commission of the Jagiellonian
University and each patient signed the informed
consent for participation in the trial.
H. pylori culture and susceptibility testing
Bacterial culture. Bioptates were homoge-
nized in glass sterile mortars and inoculated onto the
solid medium ñ Schaedler agar with 5% sheep blood
(bioMÈrieux, France) and medium, Schaedler agar
with 5% sheep blood with selective supplement
DENT (Oxoid, UK). The culture was carried out for
72 h under microaerophilic conditions at 37OC. The
presence of H. pylori in the examined material was
confirmed by the macroscopic appearance of
colonies on the medium, the Gram-stained prepara-
tion from the culture (Gram-negative, s-shaped bac-
teria) and positive tests for urease, catalase and oxi-
dase. Each H. pylori strain was frozen and stored at
ñ80OC for further analysis. 
Susceptibility testing. H. pylori drug-suscepti-
bility to levofloxacin was quantitatively tested by
strips impregnated with antibiotic gradient (E-test,
bioMÈrieux, France), which enables the determina-
tion of the minimum inhibitory concentration
(MIC). The testing was carried out as follows: the
suspension of bacteria in 0.85% NaCl sterile solu-
tion was prepared from the culture of H. pylori. The
density of the suspension amounted to 3.0
McFarland. The suspension was inoculated onto the
Schaedler agar with 5% sheep blood. After that,
strips impregnated with levofloxacin gradient (E-
test) were affixed according to the manual. The
plates were incubated under microaerophilic condi-
tions at 37OC for 72 h. The strains in which the MIC
value exceeded 1 µg/mL were considered resistant,
according to the EUCAST recommendations (25,
26). The determination was carried out against the
reference H. pylori ATCC 43504 strain to ensure the
quality of tests. 
Susceptibility testing to levofloxacin for H.
pylori strains collected between 2006ñ2010 was car-
ried out after defrosting and performing the culture
of the strains, due to the unavailability of E-test with
levofloxacin since 2010, whereas susceptibility test-
ing to levofloxacin for H. pylori strains, which were
collected between 2010ñ2012, was carried out
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immediately, together with a determination of sus-
ceptibility to other antibiotics.
Susceptibility of H. pylori strains to other
antibiotics/chemotherapeutics was tested according
to described procedures. 
Interpretations of MIC values for all described
strains to all tested antimicrobial agents were made
according to EUCAST Clinical Breakpoint Table
for H. pylori (26).
Statistical analysis
The following statistical parameters were cal-
culated: mean values, probability, χ2 test at the 0.05
significance level (the results in which p ≤ 0.05 were
considered statistically significant). In cases where
the expected values were less than 5, the Yates cor-
rection was used.
RESULTS
In total, 811 patients with dyspeptic symptoms
were enrolled in the study. The presence of H. pylori
infection was confirmed in 210 cases: 115 women and
95 men, which shows that both ganders were equally
represented. The average age of patients was 45 years. 
Two hundred ten strains from 210 dyspeptic
patients were included in the study. In total, 81%
(171/210) strains were derived from patients before
the treatment of H. pylori infection and 19%
(39/210) were derived from patients after the unsuc-
cessful treatment of H. pylori infections. 
The susceptibility of H. pylori strains to levo-
floxacin was quantitatively determined by the E-
test. The obtained MIC values ranged from 0.002
mg/L to 32 mg/L. The mean MIC values amounted
to 1.01 mg/L (Figure 1). 
In total, the ratio of H. pylori strains resistant to
levofloxacin amounted to 8.10% (17/210), whereas
the percentage of strains susceptible to levofloxacin
amounted to 91.90% (193/210). The probability of
the incidence of resistance to levofloxacin among H.
pylori strains isolated from patients who were
included into the trial was low and amounted to
P(A) = 0.081. 
In the group of 17 resistant to levofloxacin H.
pylori strains, there were more strains isolated from
women than from men (11 and 6; respectively).
Among the group of H. pylori strains isolated
from patients before the treatment, 5.85% (10/171)
of H. pylori strains were resistant to levofloxacin,
Figure 1. Activity of levofloxacin against H. pylori strains expressed by MIC values; MIC > 1 mg/L for resistant strains 
Table 3. Comparison of H. pylori resistant strains isolated from patients before treatment and after failed therapy to levofloxacin (LE) out
of 210 clinical H. pylori isolates.
No. (%) of resistant strains 
Antimicrobial Strains from patients Strains from patients 
agent
All strains
before treatment after failed therapy p*n = 210
n = 171 n = 39
LE 17 (8.10%) 10 (5.85%) 7 (17.95%) 0.0297**
* p (test χ2 with Yates correction; the value p = 0.05 was deemed statistically significant;
** significant differences between H. pylori strains resistant to levofloxacin from patients before and after treatment
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whereas in the group of strains isolated from
patients after the treatment 17.95% (7/39) of strains
were resistant to this quinolone. The statistical
analysis was performed in order to check if differ-
ences between percentages of H. pylori strains
resistant to levofloxacin from patients before and
after the treatment were significant and this was the
case (p = 0.0297) (Table 3). 
Moreover, the analysis of the coexistence of
resistance to levofloxacin and other antibiotics was
conducted. Six from 17 strains were only resistant
to levofloxacin and no other antibiotics. Eleven
strains were resistant to more than one antibiotic
(Table 4). 
DISCUSSION
An increasing resistance of H. pylori strains to
currently used antibiotics and chemotherapeutics is
a serious therapeutic problem. A properly selected
treatment model is very important as it enables H.
pylori eradication, decreases the risk of drug-resist-
ant strains occurrence and increases the probability
of the successful therapy. Considering the high
resistance of H. pylori strains to clarithromycin in
Poland, according to Maastricht/Florence
Consensus, levofloxacin should be introduced into
the basic therapeutic schemes, as most of H. pylori
strains are susceptible to this fluoroquinolone (1).
An introduction of levofloxacin to the treatment reg-
imens provides new possibilities to achieve effective
H. pylori eradication.
The results of the study confirmed that sub-
stantial majority (91.90%) of isolated H. pylori
strains are in vitro susceptible to levofloxacin.
Furthermore, the low probability of incidence of H.
pylori resistance to levofloxacin (P(A) = 0.081) was
demonstrated. The results revealed that in the
Ma≥opolska region (Southern Poland) the resistance
of H. pylori to levofloxacin is low and rather rare
(8.10%). Therefore, an introduction of this fluoro-
quinolone to the therapy of H. pylori infections may
raise the rate of H. pylori eradication. Nevertheless,
it is worth seeing that in the group of patients after
the failed therapy, the percentage of resistant strains
is statistically higher than in the group of patients
before the treatment (17.95% vs. 5.85%; p =
0.0297), however, it is still lower than the resistance
to clarithromycin and metronidazole. In this respect,
an introduction of levofloxacin to the 2nd line thera-
py seems to be a good solution. Moreover, it has
been demonstrated that most H. pylori strains resist-
ant to clarithromycin and metronidazole retain their
susceptibility to levofloxacin (27, 28). Nonetheless,
as shown Table 4, our study revealed the occurrence
of H. pylori strains resistant to levofloxacin and cla-
rithromycin or metronidazole or both these drugs.
Therefore, it should be stressed the necessity of
monitoring the resistance of H. pylori strains. 
It should be underlined that the percentage of
strains resistant to fluoroquinolones differs depend-
ing on the geographic region. It ranges from 5.3% in
Iran (29), 14.3% in Japan, 16.8% in Belgium (25),
17.0% in Brazil to 22.1% in Germany (30). 
The study performed by Zullo et al., in Italy in
2007 on 246 H. pylori strains isolated from dyspep-
tic patients showed that 19.1% of strains were resist-
ant to levofloxacin (30). The study demonstrated an
increase of the resistance to levofloxacin in that
region, as Gatta et al., had reported the ratio of 14%
of H. pylori strains resistant to levofloxacin earlier
(in 2005) (24). The resistance increases also in other
countries, e.g., in France it rose from 3.3% in 1999
to 17.5% in 2003 (25). The problem of an increasing
resistance of H. pylori to quinolines is an effect of
their frequent use in the treatment of many diseases,
for instance those affecting airways or the urinary
tract (31ñ33).
Results of many clinical trials have confirmed
the effectiveness of levofloxacin in the therapy (27,
28, 34ñ36). Levofloxacin may constitute a good
alternative in the case of double resistance of H.
Table 4. Co-existence of H. pylori strains resistant to levofloxacin and other antibiotics.
H. pylori resistant to: No. of resistant H. pylori strains
LE 6
LE + CH 1
LE + MZ 2
LE + CH + MZ 8
All 17  
LE ñ levofloxacin, CH ñ clarithromycin, MZ ñ metronidazole
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pylori strains to clarithromycin and metronidazole as
these strains retain susceptibility to levofloxacin
(23, 27, 37). 
Gatta et al. showed that the administration of
levofloxacin with amoxicillin and PPI for 10 days
as a third-line therapy affects the curability in over
80% (24). Gispert et al. obtained H. pylori eradi-
cation in 60ñ66% using the same therapeutic
scheme, whereas Zullo reported eradication of
83% (38, 39). 
In Spain, side effects and the effectiveness of
the treatment of H. pylori infections were examined
by using levofloxacin combined with amoxicillin
and PPI as the first-line therapy. The study was car-
ried out in comparison to the control group where
PPI, clarithromycin and amoxicillin were adminis-
tered. It was shown that the tolerance to levofloxacin
was good. However, in the trial group, H. pylori
eradication was lower as compared to the control
group (71.8 and 75.5%, respectively) (40).
Nista et al. compared the effectiveness of H.
pylori treatment between the following regimens:
ñ group 1: PPI, clarithromycin (500 mg),
amoxicillin (1 mg),
ñ group 2: PPI, clarithromycin (500 mg),
metronidazole (500 mg),
ñ group 3: PPI, clarithromycin (500 mg), levo-
floxacin (500 mg).
The rate of H. pylori eradication in these
groups amounted to 75, 72 and 87%, respectively.
Thus, the use of levofloxacin combined with PPI
and clarithromycin gave better results than typical
first-line therapeutic schemes (21). 
The use of levofloxacin provides new treat-
ment opportunities as the drug shows good tolerance
and gives good therapeutic effects. Levofloxacin
can be used as an alternative to amoxicillin in indi-
viduals sensitive to penicillins (34). Moreover, levo-
floxacin gives a higher curability rate in comparison
to other therapeutic schemes, such as the standard 2nd
line therapy ñ the quadruple therapy containing bis-
muth salts (41). The administration of a lev-
ofloxacin-based triple therapy for 10 days is more
effective than the quadruple therapy containing bis-
muth salts used for 7 days (32).
CONCLUSION
The introduction of the 2nd line levofloxacin-
based triple therapy is a good alternative in the
treatment of H. pylori infections, especially in
regions with high prevalence of H. pylori strains
resistant to clarithromycin, like Poland.
Nevertheless, a need for the local national resistance
monitoring of H. pylori resistant strains should be
stressed, because of the possibility of acquiring fast
resistance to levofloxacin.
Moreover, it should be considered if triple ther-
apy with levofloxacin will be better solution of 1st
line treatment in region with high prevalence of H.
pylori strains resistant to clarithromycin and
unavailability of bismuth, instead of quadruple non-
bismuth therapy that consists clarithromycin.
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